We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
+26.22%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$475M
AUM Growth
+$226M
(+91%)
Cap. Flow
+$193M
Cap. Flow
% of AUM
40.57%
Top 10 Holdings %
Top 10 Hldgs %
41.72%
Holding
154
New
62
Increased
25
Reduced
13
Closed
48
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$7.96M |
| 2 |
Amgen
AMGN
|
+$5.99M |
| 3 |
Azenta
AZTA
|
+$5.35M |
| 4 |
Establishment Labs
ESTA
|
+$5.33M |
| 5 |
Centene
CNC
|
+$5.26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SIEN
Sientra, Inc.
SIEN
|
+$3.59M |
| 2 |
HOLX
Hologic
HOLX
|
+$3.48M |
| 3 |
ATHN
Athenahealth, Inc.
ATHN
|
+$3.34M |
| 4 |
AGN
Allergan plc
AGN
|
+$3.33M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$2.55M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 35.48% |
| 2 | Industrials | 0.59% |
| 3 | Technology | 0.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$811B
| $62.5M | 13.15% |
215,000
+202,500
| +1,620% | +$57.7M |
|
2
PUT
iShares Russell 2000 ETF
IWM
$81.9B
| $37.9M | 7.98% |
225,000
+180,000
| +400% | +$30.4M |
|
3
CALL
LivaNova
LIVN
$4.54B
| $26M | 5.48% |
210,000
+15,000
| +8% | +$1.77M |
|
4
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.5B
| $11.9M | 2.5% |
125,000
+65,000
| +108% | +$5.87M |
|
5
ICU Medical
ICUI
$4.31B
| $11.7M | 2.46% |
41,319
+17,319
| +72% | +$5.07M |
|
6
Inspire Medical Systems
INSP
$1.88B
| $10.2M | 2.16% |
243,493
+43,213
| +22% | +$2.03M |
|
7
CALL
Medtronic
MDT
$109B
| $9.84M | 2.07% |
+100,000
| New | +$9.25M |
|
|
8
Boston Scientific
BSX
$69.8B
| $9.74M | 2.05% |
252,925
+227,925
| +912% | +$7.96M |
|
|
NVO
9
CALL
Novo Nordisk
NVO
$209B
| $9.43M | 1.98% |
+400,000
| New | +$9.76M |
|
|
10
CALL
ICU Medical
ICUI
$4.31B
| $9.05M | 1.9% |
32,000
-3,000
| -9% | -$879K |
|
|
11
LivaNova
LIVN
$4.54B
| $8.79M | 1.85% |
70,871
+821
| +1% | +$96.8K |
|
12
PUT
First Trust Health Care AlphaDEX Fund
FXH
$1.05B
| $8.49M | 1.79% |
+100,000
| New | +$7.98M |
|
|
13
Medtronic
MDT
$109B
| $7.97M | 1.68% |
81,027
+31,027
| +62% | +$2.87M |
|
14
CALL
Abbott
ABT
$182B
| $7.34M | 1.54% |
+100,000
| New | +$6.57M |
|
15
CALL
DexCom
DXCM
$32.7B
| $7.15M | 1.5% |
+200,000
| New | +$6.2M |
|
16
CALL
Zimmer Biomet
ZBH
$18.4B
| $6.57M | 1.38% |
+51,500
| New | +$6.12M |
|
|
17
DexCom
DXCM
$32.7B
| $6.52M | 1.37% |
182,240
+82,240
| +82% | +$2.55M |
|
|
NSTG
18
DELISTED
NanoString Technologies, Inc.
NSTG
| $6.36M | 1.34% |
356,494
+158,377
| +80% | +$2.31M |
|
|
19
Amgen
AMGN
$204B
| $6.3M | 1.32% |
+30,373
| New | +$5.99M |
|
|
20
PUT
Amgen
AMGN
$204B
| $6.22M | 1.31% |
+30,000
| New | +$5.91M |
|
21
STAAR Surgical
STAA
$1.21B
| $5.83M | 1.23% |
121,556
+21,556
| +22% | +$883K |
|
|
VRAY
22
DELISTED
ViewRay, Inc.
VRAY
| $5.81M | 1.22% |
620,839
+187,524
| +43% | +$1.84M |
|
|
XENT
23
CALL
DELISTED
Intersect ENT, Inc
XENT
| $5.75M | 1.21% |
+200,000
| New | +$6.01M |
|
|
24
Azenta
AZTA
$1.35B
| $5.7M | 1.2% |
+162,676
| New | +$5.35M |
|
|
25
Centene
CNC
$31.7B
| $5.49M | 1.15% |
+75,810
| New | +$5.26M |
|
Similar funds
GMP
BCA
ONGA
RC
DOFI
SR
TC
PA
Pura Vida Investments's Q3 2018 Portfolio in Review
As of Q3 2018, Pura Vida Investments held 154 positions worth $475M, up 91% from $250M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Pura Vida Investments deployed $193M of net new capital in Q3 2018, opening 62 new positions and adding to 25 existing holdings. Its largest new stake was Amgen: 30,373 shares worth $6.3M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 37% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $2.36M trimmed.
- Pura Vida Investments's largest Q3 2018 buy was Amgen: 30,373 shares worth $6.3M.
- Pura Vida Investments added most to Boston Scientific in Q3 2018, an estimated $7.96M increase.
- Pura Vida Investments's biggest Q3 2018 reduction was Madrigal Pharmaceuticals, cutting an estimated $2.36M.
- Pura Vida Investments fully exited Sientra, Inc. in Q3 2018, selling an estimated $3.59M.
- Pura Vida Investments's ten largest holdings make up 42% of its $475M portfolio in Q3 2018.
- Pura Vida Investments opened 62 new positions and closed 48 in Q3 2018.
- Pura Vida Investments's portfolio value rose 91% quarter-over-quarter to $475M.
Based on Pura Vida Investments's 13F filing for Q3 2018, filed 14 Nov 2018.